Julie Hambleton - 14 Aug 2025 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Director
Signature
/s/ Julie Hambleton
Issuer symbol
IGMS
Transactions as of
14 Aug 2025
Net transactions value
$0
Form type
4
Filing time
14 Aug 2025, 20:52:50 UTC
Previous filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hambleton Julie Director C/O IGM BIOSCIENCES, INC., 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW /s/ Julie Hambleton 14 Aug 2025 0001578771

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Disposed to Issuer -2,000 -100% 0 14 Aug 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Julie Hambleton is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.